Natera, Inc. (NTRA)
NASDAQ: NTRA · Real-Time Price · USD
168.02
+1.46 (0.88%)
Sep 5, 2025, 4:00 PM - Market closed
Natera Revenue
Natera had revenue of $546.60M in the quarter ending June 30, 2025, with 32.24% growth. This brings the company's revenue in the last twelve months to $1.96B, up 44.38% year-over-year. In the year 2024, Natera had annual revenue of $1.70B with 56.75% growth.
Revenue (ttm)
$1.96B
Revenue Growth
+44.38%
P/S Ratio
11.26
Revenue / Employee
$442,997
Employees
4,434
Market Cap
23.06B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.70B | 614.34M | 56.75% |
Dec 31, 2023 | 1.08B | 262.35M | 31.99% |
Dec 31, 2022 | 820.22M | 194.74M | 31.13% |
Dec 31, 2021 | 625.49M | 234.48M | 59.97% |
Dec 31, 2020 | 391.01M | 88.68M | 29.33% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
NTRA News
- 4 days ago - Natera: A Buy As Positive Growth And Cashflow Outweigh Unprofitability - Seeking Alpha
- 8 days ago - Natera Provides Update on Patent Litigation with NeoGenomics - Business Wire
- 9 days ago - Signatera™ Test Selected for NRG-Sponsored Phase III ARCHER Trial in Bladder Cancer - Business Wire
- 12 days ago - Natera to Present Signatera™ Data at the IASLC World Conference on Lung Cancer - Business Wire
- 15 days ago - Natera Technology Featured in 300+ Peer-Reviewed Publications, Underscoring Scientific Leadership in Precision Medicine - Business Wire
- 16 days ago - Natera Launches Proprietary AI Foundation Models to Accelerate Diagnostic and Therapeutic Innovation - Business Wire
- 19 days ago - IMvigor011 Bladder Cancer Trial Achieves Positive Results, with Signatera™ Strongly Predicting Adjuvant Immunotherapy Benefit - Business Wire
- 4 weeks ago - Natera shares surge 17% after strong Q2 results and upgraded guidance - Invezz